Platelet transfusion refractoriness (PTR) is a harmful complication of platelet transfusion that leads to increased rates of morbidity and mortality. It is a very complex process, not well known, in which there are many interplaying variables. PTR consists of an inadequate response to platelet transfusions and affects more than a third of patients with hematological malignancies who have been chronically transfused. Diagnosis of PTR is a controversial issue, since there are no standard criteria and therefore different diagnose approaches have been tried. PTR have an immune or non-immune origin. Non-immune causes involve near 80% of PTR patients, being splenomegaly, sepsis, and medications the most frequent associated conditions. Development of antibodies against human leukocyte antigens (HLA) or human platelet specific antigens (HPA) represent approximately one third of refractory episodes. Despite the clinical relevance, PTR is often underdiagnosed even in hematologic patients because of the complexity of the process. Furthermore, the management of this platelet transfusion complication is often frustating, especially for non-immune causes. Therapeutic options for PTR are limited and also controversial: There are several strategies to provide HLA or HPA matched-platelets that do not produce adequate postransfusion counts in a high percentage of patients with anti-HLA or anti-HPA antibodies. The objective of this review is to update knowledge about PTR, focusing on controversial issues related to diagnose and management.
INTRODUCTION

Platelet transfusion is
AETIOLOGY
Copyright 2018 Copernicus Publishing. All rights reserved. It can provoke a vasculopathy or even a thrombocytopenic thrombotic purpura, increasing the platelet consumption. In addition, it's associated with the production of autoantibodies leading to an immunemediated destruction. 18 Hepatic sinusoidal obstruction does not seem to be directly associated with refractoriness as shown in a large study with 235 patients. 19 The same study found that 80% of transplanted patients that died from any cause were refractory to platelets, suggesting that refractoriness could be a sign of clinical deterioration. -Treating the underlying disease.
Medications
-Transfusing ABO-identical platelets of less than 48 hours. Apheresis platelets are not necessary.
-Increasing the frequency of transfusions.
-If splenomegaly is present, increasing the number (rather than frequency) of transfused platelets.
-Transfusing at least 4 hours (preferably 8-12h) after administration of amphotericin B.
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Crossmatching
It consists of incubating donor platelets 
Antibody specificity prediction
This strategy determines specificities of the recipient's alloantibodies, and the patient is -Recombinant human factor VIIa:
anecdotal success. This could be a reasonable option as a temporary measure or last resort, taking the prothrombotic risk into consideration.
SUMMARY
Platelet transfusion refractoriness is a 
